Stryker (NYSE:SYK) said last week that the American Heart Association and American Stroke Association updated guidelines on ischemic stroke based on evidence from the company-sponsored Dawn trial of its Trevo thrombectomy device.
The new recommendations shift the treatment window from six to 16 hours and state that treatment could be a reasonable course of action for up to 24 hours after a stroke, the Kalamazoo, Mich.-based company said.
“We are excited to see that the hard work and results from the Dawn trial are being embraced by the AHA. My colleagues and I are looking forward to the opportunity to improve the lives of more patients and their families,” co-primary investigator Dr. Raul Nogueira of Emory University said in a prepared statement.
The updated guidelines state that stent retrievers are the only devices proven effective at treating ischemic stroke with level 1A evidence and remain the first choice for neurointerventional treatment, Stryker said.
“Stryker is proud to partner with our customers in leading the way in treatment of this devastating disease through clinical excellence and high performing products like the Trevo XP retriever,” neurovascular division prez Mark Paul said in a press release.
Last November, Stryker released results from the Dawn trial of its Trevo thrombectomy device, touting significant effects even when used beyond six hours after stroke.
Results from the trial were published in the New England Journal of Medicine.
